DS 109

Drug Profile

DS 109

Alternative Names: DGLA - second generation; Dihomogammalinolenic-acid - second generation; DS 109A; DS109

Latest Information Update: 17 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dignity Sciences
  • Developer DS Biopharma
  • Class Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders
  • Preclinical Unspecified

Most Recent Events

  • 16 Jan 2017 Preclinical trials in Undefined indication in Ireland (PO) (DS Biopharma pipeline)
  • 06 Jan 2017 DS Biopharma completes a phase I trial in Skin disorders in Ireland
  • 06 Jan 2017 DS Biopharma plans a phase II trial in Rosacea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top